Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients
Morphological response per RECIST should not be the aim of NAT in patients with PDAC. Conversely, the proportion of VTC could be a reproducible, simple, and effective prognostic tool. Should this marker be further confirmed as valuable, it may help inform the adaptation of adjuvant treatment and follow-up in this setting.
Authors
- M. Ronot
- Riccardo Sartoris (ORCID: https://orcid.org/0000-0001-5890-0341)
- Anaïs Jenvrin (ORCID: https://orcid.org/0000-0002-8309-4991)
- Lucie Laurent (ORCID: https://orcid.org/0000-0003-0674-736X)
- Anne-Laure Vedie
- Jérôme Cros (ORCID: https://orcid.org/0000-0002-4935-3865)
- A Couvelard
- Matthieu Tihy (ORCID: https://orcid.org/0000-0002-9314-4657)
- L. De Mestier
- Claire Bongrain
- Safi Dokmak
- Vinciane Rebours
- Alain Sauvanet
Institutions
- Université Paris Cité (FR)
- Hôpital Beaujon (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/17588359251403909
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00